Patient description: The patient is a 15 year old girl with the history of recurrent bilateral headache. The attacks come 2 times or more per week and each episode lasts around a day or a half. The pain is pulsating in quality and severe in intensity, causing trouble in her routine physical activity. The attacks are associated with nausea and photophobia. She recently noticed that that there are more attacks around her menstrual period. She is diagnosed with the migraine headache and is under treatment. She is a high-school student and living with her both parents. She is a book worm and spend her free time in a public library near her home. She is also interested in writing stories and has several short stories in English. She rarely does exercise. Her BMI is 21 with the BP of 100/60. There is nothing remarkable in her physical exam.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Migraine Disorders Man and women with an acute onset of acute migraine headache with or without aura of moderate to severe intensity Established diagnosis of migraine (with or without aura) according to International Headache Society (IHS) for >= 1 year; age of onset <= 50 years Current age is 18-65 years Study drug treatment to begin in less than 6 hours of the onset of migraine headache which is not spontaneously improving. Time of awakening with a migraine headache is considered as time of onset provided no headache was present prior to sleep History of 1 to 6 migraine headaches per month for the preceding 6 months Ability to give written informed consent in accordance with International Committee on Harmonisation Good Clinical Practice (ICH-GCP) and local legislation  Use of prescription and non-prescription medications for migraine prophylaxis within 2 weeks prior to treatment including Selective Serotonin Reuptake Inhibitors (SSRIs) (except fluoxetine which should have a 6 weeks washout), flunarizine (which should have a 4 week washout) and Mono-amino-oxidase-inhibitors drugs (MAOIs) Use of paracetamol (acetaminophen), aspirin, Non-steroidal anti-inflammatory drugs (NSAIDS), barbiturates or anti-emetics within 12 hours of taking study drug or of any 'triptan', ergotamine preparation or opiate analgesics within 48 hours prior to study drug administration or the use of analgesics > 10 days/months History of significant medical (i.e. coronary artery disease by history, renal failure), neurological (including epilepsy and structural brain lesions) or psychiatric disorders History, clinical evidence or screening or baseline electrocardiogram suggestive of cardiovascular disease including ischemic heart disease, Prinzmetal angina, coronary vasospasm, history of atherosclerotic heart disease of cardiac arrhythmia History of known hypertension History of basilar, ophthalmoplegic or hemiplegic migraine headaches or non-migraine headaches (e.g. tension-type headaches) occurring on average >= 10 days per month for the preceding 6 months History of treatment resistance migraine attacks defined as a lack of response to a range of commonly used acute anti-migraine compounds Females who are nursing or pregnant (as determined by a serum pregnancy test at screening and a urine pregnancy test at baseline) or of childbearing potential (any woman who is not at least 1 year post-menopausal or surgically sterile is considered to be of childbearing potential) and not using a medically approved method of birth control as defined by local country requirements Baseline systolic BP >= 160 mmHg or diastolic BP >= 100 mmHg Any daily intake of prescribed medication within 2 weeks prior to randomization for diseases in the investigator's judgment that would contraindicate participation in the trial